| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Black Hawk Acquisition Corporation Class A Ordinary Shares$11.91
0 (0%)
Market Cap
48.14 M
EPS
0.16
P/E Ratio
73.92 $
Value Trade
2.51 K
SEC Financials
Q1 2026Dilution Risk
Operating CF
-109.50 K
Total Assets
24.82 M
Total Liabilities
4.70 M
Equity
-4.52 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
-
Monthly Burn
37.00 K
Runway
0 mo
Burn Trend
SEC Filing
Apr 21, 2026
Overview
Volume
3.52 K
52 Week Range
10.53 - 11.95
% held by Insiders
11.47 %
% held by Institutions
50.15 %
Enterprise Value
49.27 M
Total Shares
4.15 M
Short %
0 %
Float Shares
2.19 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BKHA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Black Hawk Acquisition Corporation Class A Ordinary Shares (BKHA) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
BKHA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BKHA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BKHA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BKHA Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
BKHA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-BKHA
Mar 17, 2026Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer Blackhawk, Calif.
Vesicor Therapeutics has appointed Dr. Michael Tolentino, M.D., as its new Chief Executive Officer, effective March 17, 2026. Dr. Tolentino, an accomplished figure in the biotech industry, succeeds the company's founder Luo Feng, who will now serve as Chief Scientific Officer. The company is focusing on advancing its p53-based cancer therapeutics and is currently pursuing a proposed merger with Blackhawk Acquisition Corporation. Dr. Tolentino expressed his commitment to build upon the company’s technology and accelerate its development towards an IND submission in 2027.
Read more →-BKHA
Jul 7, 2025Black Hawk Acquisition Corporation Amends Its Definitive Proxy Statement
Black Hawk Acquisition Corporation has filed a supplement to its definitive proxy statement to amend the Trust Amendment Proposal. The amendment changes the deposit requirement for extensions related to initial business combinations from an amount based on outstanding shares to a fixed amount of $150,000 per month. This update aims to eliminate ambiguity regarding deposit amounts and reinforce the company's obligations. The press release indicates there are risks associated with forward-looking statements.
Read more →-BKHA
Apr 28, 2025Vesicor Therapeutics, Inc. and Black Hawk Acquisition Corporation Enter into a Business Combination Agreement to Create a Biotechnology Company Advancing p53-based Cancer Therapeutics Delivered Via Microvesicles Transact
Vesicor Therapeutics, Inc. has entered into a Business Combination Agreement with Black Hawk Acquisition Corporation to create a biotechnology company focused on p53-based cancer therapeutics. This transaction will pave the way for Vesicor to become a public company and to access capital for advancing its drug candidate, ecm-RV/p53, which is aimed at treating various forms of cancer. The deal, valued at $70 million, is expected to close by the fourth quarter of 2025, subject to regulatory and shareholder approvals. Vesicor plans to initiate preclinical testing and begin clinical trials in the near future.
Read more →-BKHA
Apr 23, 2024Black Hawk Acquisition Corporation Welcomes Mr. Jonathan Ginsberg to Board Danville, CA.
Black Hawk Acquisition Corporation has appointed Mr. Jonathan Ginsberg as a director and Chief Operating Officer. Ginsberg, age 33, brings valuable experience from international trade and education, previously serving as President of BEEC Inc. His appointment is seen as a strategic move to enhance the company’s leadership without any disclosed conflicts with current board members.
Read more →-BKHA
Mar 22, 2024BLACK HAWK ACQUISITION CORPORATION INDEX TO FINANCIAL STATEMENT Page Report of Independent Registered Public Accounting Firm (PCAOB ID: 206) F-2 Financial Statement (Audited): Balance Sheet as of
Black Hawk Acquisition Corporation has released its independent auditor's report and financial statements as of March 22, 2024. The audit indicates that the financial position presents fairly, however, there are significant concerns regarding the company's ability to operate as a going concern. The company is dependent on successfully completing a business combination within a certain timeframe, failing which it will have to liquidate. Financial highlights include total assets of approximately $70.3 million, with a shareholder deficit of about $1.8 million.
Read more →-BKHA
Mar 20, 2024Black Hawk Acquisition Corporation Announces Pricing of $69,000,000 Upsized Initial Public Offering Danville, CA.
Black Hawk Acquisition Corporation announced the pricing of its initial public offering at $69 million, consisting of 6,900,000 units priced at $10.00 each. The units are set to trade on the NASDAQ under the ticker symbol "BKHAU" beginning March 21, 2024. The IPO includes options for underwriters to purchase additional units, with the transaction expected to close by March 22, 2024, pending customary conditions. This offering marks a significant step for the company as it seeks to pursue business combinations.
Read more →Competitive Position
How BKHA ranks across every disease it competes inCompetitive Position is a premium feature
See how BKHA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial